<span id="v9r9v"><video id="v9r9v"></video></span>
<strike id="v9r9v"><video id="v9r9v"></video></strike>
<th id="v9r9v"></th>
<th id="v9r9v"></th>
<span id="v9r9v"><video id="v9r9v"></video></span>
<progress id="v9r9v"><noframes id="v9r9v"><span id="v9r9v"><noframes id="v9r9v">
您的位置:首頁>>分析化學>>藥物分析標準品>>S5868 SORAFENIB 284461-73-0
Cat. Number
S5868
Chemical Name
S5868 SORAFENIB 284461-73-0
CAS Number
284461-73-0
Mol. Formula
C21H16ClF3N4O3
Mol. Weight
464.82
Qty 1
25mg
Qty 2
100mg
Appearance
White to off white powder
Application Notes
≥98%
Synonym
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide, BAY 43-9006
Melting Pt.
202-204°C
Solubility
DMSO 127mg/mL, water:0.01mg/mL
Storage condition
Ambient
References

Sorafenib is an inhibitor of c-Raf, Ret, and VEGFR2 that is currently used clinically to treat renal cell carcinoma and hepatocellular carcinoma, as well as other advanced cancers. Sorafenib exhibits anticancer chemotherapeutic, anti-angiogenic, and immunosuppressive activities. In osteosarcoma cells, sorafenib inhibits cell proliferation by downregulating expression of ERK and VEGFR2 and inhibiting phosphorylation of VEGFR2, RET, and MEK1. In cellular and animal models of lymphoma, sorafenib inhibits phosphorylation of MAPKs and PI3K/Akt, decreasing vessel density and increasing apoptotic cell death. Sorafenib also inhibits the epithelial-to-mesenchymal transition (EMT) in epithelial cells and potentiates histone acetylation. In hepatoma cells, this compound decreases levels of enhancer of zeste homolog 2 (EZH2) and inhibits histone methyltransferase (HMT) activity, inducing apoptosis. In animal models, sorafenib inhibits tumor growth, increases tumor-specific T cells, and decreases CD8+ and Treg T cell functions by inducing T cell apoptosis. Additionally, sorafenib inhibits phosphorylation of STAT3/5.


References

Mei J, Zhu X, Wang Z, et al. VEGFR, RET, and RAF/MEK/ERK Pathway Take Part in the Inhibition of Osteosarcoma MG63 Cells with Sorafenib Treatment. Cell Biochem Biophys. 2013 Dec 31. [Epub ahead of print]. PMID: 24375110.

Chen ML, Yan BS, Lu WC, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer. 2013 Jul 2. [Epub ahead of print]. PMID: 23818246.

Wang S, Zhu Y, He H, et al. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. Cancer Sci. 2013 Jun;104(6):750-9. PMID: 23421437.

Zhang J, Chen YL, Ji G, et al. Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells. PLoS One. 2013 May 31;8(5):e64954. PMID: 23741434.

Carlo-Stella C, Locatelli SL, Giacomini A, et al. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PLoS One. 2013 Apr 19;8(4):e61603. PMID: 23620775.

Panka DJ, Wang W, Atkins MB, et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res. 2006 Feb 1;66(3):1611-9. PMID: 16452220.


下一個:TMP-269上一個:SCRIPTAID
在線咨詢 聯系方式 二維碼

服務熱線

021-60498804

掃一掃,關注我們

人妻a∨中文字幕,亚洲AV日韩AV永久无码绿巨人,一国产永久视频,2022一本久道久久综合狂躁,国产欧美日韩在线视频一区 日韩精品Aⅴ无码AV 狠狠久夜一区二区三区 亚洲国产精品无码高潮 精品无码一区二区三在线观看 專業选择!国际品质好吊操视频 中文字幕一区二区人妻本田岬 久久综合电影一区 日韩AV不卡一区二区三区无码 欧美色欧美亚洲日韩在线播放